Loading provider…
Loading provider…
Neurology Physician in Pittsburgh, PA
NPI: 1093717092Primary Practice Location
ALLEGHENY GENERAL HOSPITAL
320 E North Ave, Pittsburgh, PA
Primary Employer
Ahn Neurology
ahn.org
HQ Phone
Get MD Thomas's Phone Numberphone_androidMobile
Get MD Thomas's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardPA State Medical License
West Virginia University School Of Medicine
medicine.wvu.edu
Medical School
Until 1985
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 85 | 109 |
| 2 | 99213Established patient office or other outpatient visit, typically 15 minutes | 71 | 86 |
| 3 | 99223Initial hospital inpatient care, typically 70 minutes per day | 50 | 50 |
| 4 | 99232Subsequent hospital inpatient care, typically 25 minutes per day | 34 | 52 |
| 5 | 99215Established patient office or other outpatient, visit typically 40 minutes | 31 | 34 |
MRI predictors of early conversion to clinically definite MS in the CHAMPS placebo group
Authors: Steven Galetta, Andrew Blumenfeld
Publication Date: 2002-10
The Immunological Capacity of Thrombocytes.
Authors: Ferdous, Farzana, Scott, Thomas
Journal: Int J Mol Sci
Publication Date: 2023-08-18
Measurement of treatment response to sertraline in depressed multiple sclerosis patients using the Carroll scale
Authors: Thomas F. Scott, Paul Nussbaum, Harry McConnell, Paul Brill
Publication Date: 1995-12
Lead Sponsor: Genzyme, a Sanofi Company
Collaborators: Bayer
Intervention / Treatment: BIOLOGICAL: Interferon beta-1a, BIOLOGICAL: Alemtuzumab
Lead Sponsor: Genzyme, a Sanofi Company
Intervention / Treatment: DRUG: alemtuzumab GZ402673
Lead Sponsor: Genzyme, a Sanofi Company
Collaborators: Bayer
Intervention / Treatment: BIOLOGICAL: alemtuzumab